EA Pharma Co., Ltd. for medical professional

Eisai Group

Time to Occurrence of First Spontaneous Bowel Movement

For information on warnings, contraindications, and precautions, please refer to the "Drug information" page in the package insert.

Efficacy “Japanese Phase 3 Study6,29

[Secondary endpoints]
Time to the occurrence of first spontaneous bowel movement (FAS)

The median time to the occurrence of the first spontaneous bowel movement was 25.5 hours in the placebo group and 5.2 hours in the GOOFICE® group. The results of estimation by the Kaplan-Meier method and the log-rank test showed that the time to the occurrence of the first spontaneous bowel movement in the GOOFICE® group was significantly shorter than that in the placebo group (p = 0.0001).


<Secondary endpoint> Time before the first SBM
<Secondary endpoint> Time before the first SBM

[Secondary endpoints]
Percentage of patients who had spontaneous bowel movement within 24 hours and 48 hours after the start of administration of the investigational product (FAS)

The percentage of patients with the occurrence of spontaneous bowel movement within 24 hours after the start of administration of the investigational product was 41.3% (26/63 patients) in the placebo group and 85.5% (59/69 patients) in the GOOFICE® group. The percentage of the patients with the occurrence of spontaneous bowel movement was significantly higher in the GOOFICE® group than in the placebo group (p < 0.0001 Fisher's exact test). The percentage of patients with the occurrence of spontaneous bowel movement within 48 hours after the start of administration of the investigational product was 69.8% (44/63 patients) in the placebo group and 92.8% (64/69 patients) in the GOOFICE® group. The percentage of the patients with the occurrence of spontaneous bowel movement was significantly higher in the GOOFICE® group than in the placebo group (p = 0.0012, Fisher's exact test).


  • Percentage of patients who experienced SBM
    within 24 hours after the start of the
    investigational product

    <Secondary endpoint> Percentage of patients who experienced SBM within 24 hours after the start of the investigational product


  • Percentage of patients who experienced SBM
    within 48 hours after the start the
    investigational product

    <Secondary endpoint> Percentage of patients who experienced SBM within 48 hours after the start the investigational product
6）EA Pharma Co., Ltd.: In-house data (investigation of efficacy and safety in patients with chronic constipation) <Data submitted for review for approval>
29）Nakajima A, et al.：Lancet Gastroenterol Hepatol 2018；3（8）：537-547
（The authors include those who have received an advisory fee from EA Pharma Co., Ltd.
This study was supported by EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd.）

This site uses cookies to provide better content, analyze access, and improve the convenience of the site. By continuing to browse this site, you agree to the use of cookies. For more information and to change cookie settings, please click here.

You are now leaving the EA Pharma website.

Thank you for browsing the EA Pharma website.
You are about to visit an external website.
(A new browsing window will be opened)

Click here to proceed

The Section is for Medical Professionals.

Terms of Use

The purpose of the section is to provide useful information to medical professionals (doctors, dentists, pharmacists, nurses, nutritionists, care workers, etc.) working in medical institutions.
Please note that the section is not intended to provide information to medical professionals outside of the approved countries, nor to the general public.

Doctor, Nurse, Pharmacist, Other Medical Professionals

If you are not a medical professional

Return to Top Page